Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis

Objective: to compare the clinical efficacy in real clinical practice of the targeted synthetic disease-modifying antirheumatic drug (sDMARD) tofacitinib (TOFA) and the biologic DMARD (bDMARD), an inhibitor of tumor necrosis factor alpha (TNFα), adalimumab (ADA) in patients with psoriatic arthritis...

Descripción completa

Detalles Bibliográficos

Autores principales:	E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, S. I. Glukhova, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeyeva, E. L. Nasonov
Formato:	Artigo
Lenguaje:	Russo
Publicado:	IMA-PRESS LLC 2021-06-01
Colección:	Современная ревматология
Materias:	psoriatic arthritis tofacitinib adalimumab biologic disease-modifying antirheumatic drug targeted synthetic disease-modifying antirheumatic drug remission minimal disease activity
Acceso en línea:	https://mrj.ima-press.net/mrj/article/view/1145
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!